en · de · es · fr · pt
sr9009-notes.peptides6608.com › Guide › Analytical Detection And Laboratory Handling — Worked Examples

Analytical Detection And Laboratory Handling — Worked Examples

By Editorial Desk · published 2025-08-25 · last reviewed 2025-09-09 · Guide

Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-09. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Sr9009 at a glance

PropertyValueNotes
AppearanceOff-white to pale yellow solidVisual description varies with purity and source
SolubilitySoluble in DMSO and ethanol; poorly soluble in waterOrganic stock solutions are common in research
Typical storage-20 °C, desiccated, protected from lightAvoid repeated freeze-thaw cycles
Typical analytical methodLC-MS or HPLC-UVReference standards are needed for quantification
Molar massApproximately 437.9 g/molCalculated from the reported free-base formula

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Related pages on this site

Analytical Detection and Storage

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Handling Storage and Quality Control

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Further detail

The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the best dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, phase I trials usually include only a small number of patients who have not been helped by other treatments. (NCI) Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. (NLM) Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80.

In 2020, world production of soybeans was over 353 million tonnes, led by Brazil and the United States combined with 66% of the total (table). Production has dramatically increased across the globe since the 1960s, but particularly in South America after a cultivar that grew well in low latitudes was developed in the 1980s. The rapid growth of the industry has been primarily fueled by large increases in worldwide demand for meat products, particularly in developing countries like China, which alone accounts for more than 60% of imports. Soy is a staple crop; global soy production accounts for four times more legume production than all other legumes combined.

acid 1. (Brønsted–Lowry acid) Any chemical species or molecular entity that acts as a proton donor when reacting with another species, because it loses at least one proton (H+) which is then transferred or 'donated' to the other species, which by definition is a Brønsted–Lowry base. When dissolved in an aqueous solution, a proton donor which increases the concentration of hydronium ion (H3O+) by transferring protons to water molecules may also be called an Arrhenius acid. The term "acid", when not otherwise qualified, often refers implicitly to a Brønsted–Lowry acid. 2. (Lewis acid) Any chemical species or molecular entity that acts as an electron pair acceptor when reacting with another species, forming a covalent bond by accepting a lone pair of electrons donated by the other species, which is known as a Lewis base. This definition was intended as a generalization of the Brønsted–Lowry definition by proposing that acid-base reactions are best viewed as reorganizations of electrons rather than transfers of protons, with the acid being a species that accepts electron pairs from another species either directly or by releasing protons (H+) into the solution, which then accept electron pairs from the other species. The Lewis definition is inclusive of many Brønsted–Lowry acids, though not all: most Lewis acids are not Brønsted–Lowry acids, and most Brønsted–Lowry acids are not Lewis acids. 3. Colloquially, any compound which, when dissolved in water, yields a pH of less than 7.0.

Head of Change and Labs, Information and Digital Directorate, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Dr. Rosemary Joy Trevelyan. Director, The Tropical Biology Association. For services to Environmental Science and International Conservation. Pamela Vipond. Deputy Director, Olympic Solidarity, the International Olympic Committee. For services to Sport. Paul Walker. Co-Founder and Co-Director, Wildtracks, Belize. For services to Conservation and Biodiversity in Belize. Zoe Elizabeth Walker. Co-Founder and Co-Director, Wildtracks, Belize. For services to Conservation and Biodiversity in Belize. David Justin Warmback. Honorary Consul, Durban, South Africa. For services to British Nationals in South Africa. Christopher Michael Wicker. President and Trustee, Hertford British Hospital Charity; Secretary General, Save the Valletta Skyline Appeal. For services to Charity and to British Nationals in France and Malta. Steven Leonard Williams. Kyaninga Child Development Centre and Kyaninga Forest Foundation, Uganda. For services to Disabled Children and Local Communities in Western Uganda.

=== By age uncertainty (±σ) === There are no set limit for age uncertainty and the cut-off value varies with different precision requirement. Although excluding data with huge age uncertainty would enhance the overall zircon grain age accuracy, over elimination may lower overall research reliability (decrease in size of the database). The best practice would be to filter accordingly, i.e. setting the cut-off error to eliminate reasonable portion of the dataset (say <5% of the total ages available)

Sources: en.wikipedia.org

Background from the literature

=== Mechanism of action === Posaconazole works by disrupting the functions of certain fungal and protozoal membrane-bound enzyme systems. It does this by blocking the synthesis and turnover of the eukaryotic cell membrane component ergosterol via the inhibition of an enzyme known as CYP51. Posaconazole is significantly more potent at binding to CYP51 than itraconazole.

His work has also examined the changing role of behavioral treatment when used with GLP-1 medications, as well as the psychiatric safety of the new drugs. With colleague Gary Foster, Wadden developed the Weight and Lifestyle Inventory (WALI), a widely used self-report tool for obesity assessment, including in bariatric surgery programs. He has published more than 500 refereed papers and 40 book chapters, and co-edited seven books, including Handbook of Obesity Treatment. Since 2020, he has been recognized by Clarivate as a Highly Cited Researcher across multiple fields.

Paramagnetic Fluorescence Quenching, the allowance of new electronic states upon binding a paramagnetic metal atom Photoinduced Electron Transfer (PET), the blocking of a lower energy state due to the binding of a metal atom. Photoinduced Charge Transfer (PCT), the modulation of energy levels in a complex by charge transfer within a conjugated pi system. Fluorescence Resonance Energy Transfer (FRET), the transfer of an exciton from a donor to an acceptor, modulating the emission spectrum. Excimer/Exciplex formation, the formation of a state that is a hybrid of the ground and excited states. This has novel fluorescent properties. Chemodosimeters, complexes that undergo irreversible reactions with other species upon binding a metal to form new compounds with novel fluorescent spectra. Fluorophores are essential to some measurement of the metal binding event, and indirectly, metal concentration. There are many types, all with different properties that make them advantageous for different applications. Some work as small metal sensors completely on their own while others must be complexed with a subunit that can chelate or bind a metal ion. Rhodamine for example undergoes a conformation change upon the binding of a metal ion. In so doing it switches between a colorless, non-fluorescent spirocyclic form to a fluorescent, pink open cyclic form. Quinoline based sensors have been developed that form luminescent complexes with Cd(II) and fluorescent ones with Zn(II).

Anhalt is now part of the state of Saxony-Anhalt. Baden is now part of Baden-Württemberg. Braunschweig is now part of Lower Saxony. Lippe is now part of North Rhine-Westphalia. Lübeck is now part of Schleswig-Holstein. Mecklenburg-Schwerin and Mecklenburg-Strelitz are now parts of Mecklenburg-Vorpommern. Oldenburg is now part of Lower Saxony, with its former exclaves now belonging to their neighbouring states of Rhineland-Palatinate and Schleswig-Holstein. Prussia was divided among the states of Berlin, Brandenburg, Lower Saxony, North Rhine-Westphalia, Rhineland-Palatinate, Saxony-Anhalt and Schleswig-Holstein. The erstwhile Prussian provinces of Brandenburg, Saxony, Schleswig-Holstein and Hanover formed the core of the states of Brandenburg, Saxony-Anhalt, Schleswig-Holstein and Lower Saxony, respectively. The Prussian provinces of Westphalia and Rhineland contributed most territory to the state of North Rhine-Westphalia, and Rhineland province contributed about half of the territory of the state of Rhineland Palatinate. Most of the Prussian province of Hesse-Nassau was merged with the existing state of Hesse. Some territories bordering other states were annexed to the bordering state. Also, Prussia had exclaves that were surrounded by other states. These became part of their surrounding states. All states, except Bavaria, now have territory of the former Free State of Prussia. Other former Prussian territories lying east of the rivers Neisse and Oder were lost in 1945 and are now part of Poland or Russia.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

What is known about its stability?

The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.

Why does solubility matter?

Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network